Apatinib plus pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer

Apatinib plus pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer

Bibliographic Details
Main Authors:	Shushant Chib, Ajay Gogia
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2022-01-01
Series:	Cancer Research, Statistics, and Treatment
Online Access:	http://www.crstonline.com/article.asp?issn=2590-3233;year=2022;volume=5;issue=4;spage=793;epage=794;aulast=Chib

Similar Items

Long-term effect of pegylated liposomal doxorubicin in recurrent platinum-resistant ovarian cancer: а clinical case
by: I. A. Pokataev, et al.
Published: (2015-11-01)

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
by: Zhen Yuan, et al.
Published: (2021-01-01)

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer
by: María Jesús Rubio Pérez
Published: (2017-05-01)

Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer
by: Hiroyuki Yoshida, et al.
Published: (2023-07-01)

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
by: Moore Carla L, et al.
Published: (2010-03-01)

Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients
by: Ondřej Kubeček, et al.
Published: (2015-07-01)

Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
by: Zhongmian Pan, et al.
Published: (2023-02-01)

The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials
by: Xin-Ru Li, et al.
Published: (2021-03-01)

Effectiveness of a nursing support program for patients with recurrent ovarian cancer receiving pegylated liposomal doxorubicin (Caelyx®/Doxil®)
by: N. Grenier, et al.
Published: (2015-03-01)

Case Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer
by: Wu Y, et al.
Published: (2022-09-01)

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
by: Xin-Ru Li, et al.
Published: (2022-08-01)

Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer
by: E. V. Artamonova
Published: (2016-09-01)

The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
by: Hong Zhao, et al.
Published: (2020-09-01)

Impact of PEGylated Liposomal Doxorubicin and Carboplatin Combination on Glioblastoma
by: Mohsen Ghaferi, et al.
Published: (2022-10-01)

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
by: Wischnik Arthur, et al.
Published: (2010-01-01)

Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
by: Hong Zhao, et al.
Published: (2021-02-01)

The role of size in PEGylated liposomal doxorubicin biodistribution and anti‐tumour activity
by: Saba Dadpour, et al.
Published: (2022-09-01)

Pegylated liposomal doxorubicin (Caelyx): contemporary aspects of its application in hematology
by: O. A. Rukavitsin, et al.
Published: (2022-11-01)

Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: A single‐center retrospective study
by: Wei Chen, et al.
Published: (2020-08-01)

Successful avatrombopag combined with cyclosporine treatment for carboplatin/pegylated liposomal doxorubicin/bevacizumab-induced acquired amegakaryocytic thrombocytopenia in a patient with recurrent ovarian cancer: case report
by: Weikang Meng, et al.
Published: (2024-02-01)

Biomarkers of PEGylated Liposomal Doxorubicin-Induced Hypersensitivity Reaction in Breast Cancer Patients Based on Metabolomics
by: Wei Zhuang, et al.
Published: (2022-04-01)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
by: Lin-Quan Tang, et al.
Published: (2023-03-01)

Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
by: Francesco Schettini, et al.
Published: (2021-09-01)

Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
by: Zhongyu Wang, et al.
Published: (2021-07-01)

The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
by: K. E. Borisov
Published: (2014-07-01)

PEGylated Liposomes Remotely Loaded with the Combination of Doxorubicin, Quinine, and Indocyanine Green Enable Successful Treatment of Multidrug-Resistant Tumors
by: Emma Grabarnick (Portnoy), et al.
Published: (2021-12-01)

Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes
by: Alberto Gabizon, et al.
Published: (2023-11-01)

Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin
by: Maximilian Richter, et al.
Published: (2015-01-01)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial
by: Elena López-Miranda, et al.
Published: (2020-11-01)

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
by: Eleonora Ghisoni, et al.
Published: (2019-02-01)

Pharmacoeconomics analysis of pegylated liposomal doxorubicin (Caelyx®) in the treatment of patients with metastatic breast cancer at high risk of cardiac events
by: I. S. Krysanov
Published: (2018-05-01)

Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center
by: Salah Mabrouk Khallaf, et al.
Published: (2020-04-01)

Quantitative Cryo-TEM Reveals New Structural Details of Doxil-Like PEGylated Liposomal Doxorubicin Formulation
by: Rickard Nordström, et al.
Published: (2021-01-01)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
by: Brian A. Jonas, et al.
Published: (2023-01-01)

Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
by: Han Yao, et al.
Published: (2023-06-01)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
by: Jun Ni, et al.
Published: (2023-04-01)

Minibeam radiation therapy enhanced tumor delivery of PEGylated liposomal doxorubicin in a triple-negative breast cancer mouse model
by: Lauren S.L. Price, et al.
Published: (2021-10-01)

A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer
by: Yizhuo Xie, et al.
Published: (2023-04-01)

Pirfenidone inhibits stromal collagen deposition and improves intra-tumoral delivery and antitumor efficacy of Pegylated liposomal doxorubicin
by: Tiantian Cai, et al.
Published: (2023-01-01)

The efficacy and cardiac toxicity of different‐dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma
by: Li Li, et al.
Published: (2023-02-01)